Health Catalyst Capital
INVESTING TO TRANSFORM PERSONALIZED MEDICINE
PierianDx
Slider

Summary

PierianDx solves the problem of translating complex genomic data into actionable clinical insight to advance precision medicine. It is a cloud-based clinical genomics software platform that simplifies the process of taking DNA sequencing data though analysis, interpretation and final report. The platform is enabled by Actionable Intelligence derived from a comprehensive proprietary knowledgebase curated by a large team of scientists supported by technology and supplemented by human clinical expertise.

Our Relationship

Health Catalyst Capital led the Series A financing to support the technology transfer from Washington University in Saint Louis, a leader in Genetics and Genomics Medicine.

Team

Michael L. Sanderson, the CEO, is a healthcare strategy and growth leader. In his role at PierianDx, Sanderson will integrate the company’s unique value proposition for molecular labs into the broader precision medicine and healthcare delivery markets.

Founder and Executive Chairman Dr. Rakesh Nagarajan, MD, PhD, is trained as a physician-scientist with deep experience in molecular biology, molecular laboratory workflows and techniques. His multiple informatics subspecialties include bioinformatics, biospecimen informatics, clinical trials informatics, and medical informatics. He currently serves on the College of American Pathologists (CAP) Molecular Oncology Committee and the Next-Generation Sequencing (NGS) Project Team and is a molecular pathology specialty inspector for the CAP. He is also an Adjunct Associate Professor at the Washington University School of Medicine Department of Pathology & Immunology.